These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24827996)

  • 21. [Survival, prognostic factors and modern tendencies in adjuvant treatment of diagnosed endometrial cancer patients with or without lymph node dissection].
    Ivanov I
    Akush Ginekol (Sofiia); 2009; 48 Suppl 1():3-11. PubMed ID: 20387272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Uterine papillary serous carcinoma and papillary endometrial carcinoma: analysis of clinical biological behaviors of 56 cases].
    Sun X; Shi S; Sheng X
    Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):8-11. PubMed ID: 8758810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
    Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classification of endometrial lesions by nuclear morphometry features extracted from liquid-based cytology samples: a system based on logistic regression model.
    Zygouris D; Pouliakis A; Margari N; Chrelias C; Terzakis E; Koureas N; Panayiotides I; Karakitsos P
    Anal Quant Cytopathol Histpathol; 2014 Aug; 36(4):189-98. PubMed ID: 25291856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct histological and clinical features associated with pure uterine serous carcinoma: A single institution experience.
    Zhi W; Zhan Y; He C; Jin Y
    Ann Diagn Pathol; 2023 Oct; 66():152173. PubMed ID: 37352704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of immunoreactivity of nuclear findings by p53 and cyclin a in endometrial cytology: Comparison with endometrial glandular and stromal breakdown and endometrioid adenocarcinoma grade 1.
    Norimatsu Y; Ohsaki H; Yanoh K; Kawanishi N; Kobayashi TK
    Diagn Cytopathol; 2013 Apr; 41(4):303-7. PubMed ID: 21954041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings.
    Maneschi F; Ceccacci I; Perugini A; Pane C; Simeone A; Manicone A
    Arch Gynecol Obstet; 2012 Feb; 285(2):521-7. PubMed ID: 21779772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histologic grade and peritoneal cytology as prognostic factors in type 1 endometrial cancer.
    Tanaka K; Kobayashi Y; Sugiyama J; Yamazaki T; Dozono K; Watanabe M; Shibuya H; Nishigaya Y; Momomura M; Matsumoto H; Umezawa S; Takamatsu K; Iwashita M
    Int J Clin Oncol; 2017 Jun; 22(3):533-540. PubMed ID: 28083737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis.
    Castellvi J; Garcia A; Ruiz-Marcellan C; Hernández-Losa J; Peg V; Salcedo M; Gil-Moreno A; Ramon y Cajal S
    Hum Pathol; 2009 Oct; 40(10):1418-26. PubMed ID: 19428047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
    Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
    Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
    Salvesen HB; Das S; Akslen LA
    Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytodiagnosis of endometrial carcinoma and hyperplasia on imprint smears with additional immunocytochemistry using Ki-67 and p53 biomarkers.
    Apostolou G; Apostolou N; Nikolaidou C; Kavantzas N; Patsouris E; Athanassiadou P
    Cytopathology; 2014 Apr; 25(2):86-94. PubMed ID: 24118263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade.
    Urabe R; Hachisuga T; Kurita T; Kagami S; Kawagoe T; Matsuura Y; Shimajiri S
    J Obstet Gynaecol Res; 2014 Mar; 40(3):812-9. PubMed ID: 24246002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics of prognostic factors in poorly differentiated (G3) endometrioid adenocarcinoma in Japan.
    Kuwabara Y; Susumu N; Banno K; Hirao T; Kawaguchi M; Yamagami W; Suzuki N; Aoki D; Nozawa S
    Jpn J Clin Oncol; 2005 Jan; 35(1):23-7. PubMed ID: 15681600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precursors of endometrial clear cell carcinoma.
    Fadare O; Liang SX; Ulukus EC; Chambers SK; Zheng W
    Am J Surg Pathol; 2006 Dec; 30(12):1519-30. PubMed ID: 17122507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minor serous and clear cell components adversely affect prognosis in ''mixed-type'' endometrial carcinomas: a clinicopathologic study of 36 stage-I cases.
    Quddus MR; Sung CJ; Zhang C; Lawrence WD
    Reprod Sci; 2010 Jul; 17(7):673-8. PubMed ID: 20393071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.